Dyspepsia primary prevention
Jump to navigation
Jump to search
|
Dyspepsia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dyspepsia primary prevention On the Web |
|
American Roentgen Ray Society Images of Dyspepsia primary prevention |
|
Risk calculators and risk factors for Dyspepsia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Ajay Gade MD[3]]
Primary Prevention
Primary prevention of dyspepsia targets three modifiable domains: eradication of Helicobacter pylori, prevention of NSAID- and aspirin-related mucosal injury, and lifestyle modification.[1][2][3] Prevention of organic dyspepsia (peptic ulcer disease, H. pylori-associated dyspepsia, gastric cancer) is supported by stronger evidence than prevention of functional dyspepsia (FD), for which the benefit of lifestyle and dietary measures remains disputed.[1][4] H. pylori eradication is the only intervention with disease-modifying potential across PUD, gastric cancer, and dyspepsia.[5][6]
Helicobacter pylori Eradication
- Peptic ulcer disease: H. pylori accounts for an estimated 57% of PUD cases worldwide by population-attributable fraction, though other analyses report the organism is etiologic in approximately 42% of patients with PUD and present in 70–90% of ulcers depending on ulcer site and region.[5][7][8] A population screen-and-treat program in a high-prevalence region of Taiwan (Matsu Islands) reduced peptic ulcer disease prevalence at endoscopy from 11.0% to 3.6% (a 67% reduction) over 4 years.[9][5]
- Gastric cancer: In a 2025 meta-analysis of population-based RCTs (58,628 participants), eradication in healthy H. pylori-positive individuals reduced gastric cancer risk by 36% (39% when all RCTs were pooled), with moderate GRADE certainty.[6] Benefit is greatest when eradication precedes precancerous histologic change.[6][10]
- Dyspepsia: In H. pylori-positive FD, eradication is superior to control but the effect is modest (NNT 14 for symptom cure, 9 for improvement; high-quality evidence), with more adverse events (RR 2.19).[2] Treatment details are addressed in the medical therapy microchapter.
- Population impact: Modeling estimates that mass eradication could prevent approximately 41 million dyspepsia cases and 4.6 million PUD cases globally; an English screen-and-treat RCT found lower dyspepsia-related healthcare costs in the eradication arm.[5]
Screening Recommendations
- The AGA 2025 Clinical Practice Update endorses opportunistic, risk-based (not universal) screening for active H. pylori infection in individuals at increased gastric cancer risk (e.g., first-generation immigrants from high-incidence regions, family history of gastric cancer), with testing of household members of infected individuals.[11]
- Use a test of active infection (urea breath test or stool antigen); serology is not appropriate for screening or test of cure.[11]
- Confirm eradication ≥4 weeks after therapy and ≥2 weeks off PPI.[11]
- The optimal screening age for gastric cancer prevention is not established across populations; the Taipei consensus suggests ages 20–40.[11]
Prevention of NSAID- and Aspirin-Related Injury
NSAIDs increase the risk of PUD complications approximately 4-fold, and approximately 6-fold with concomitant H. pylori infection.[3] H. pylori eradication also reduces the risk of NSAID- and aspirin-related ulcers and prevents ulcer recurrence, per the Taipei Global Consensus II.[12] Gastroprotection is risk-stratified; patients without risk factors do not require it.[3][13]
GI risk factors: prior PUD or ulcer complication, age >65 years, high-dose NSAID therapy, and concomitant aspirin, antiplatelet agents, anticoagulants, corticosteroids, or SSRIs.[3][13]
| Strategy | Evidence and role | Limitations |
|---|---|---|
| H. pylori test-and-treat | Recommended before initiating long-term NSAID or aspirin therapy; independently lowers NSAID ulcer risk[13][14] | Need for additional gastroprotection depends on residual GI risk[13] |
| PPI co-therapy | Mainstay; standard once-daily PPI reduces incident NSAID-associated endoscopic ulcers by ~71% versus placebo (moderate-certainty evidence); class effect, not dose-dependent[15][16] | — |
| COX-2 inhibitor + PPI | Greatest protection in high-GI-risk patients (network meta-analysis, >125,000 participants)[3][17] | No lower GI tract protection; COX-2 and nonselective NSAIDs both raise cardiovascular risk; celecoxib may be preferred when GI and CV risk are both high[3][15] |
| Misoprostol | Prevents NSAID ulcers[13][15] | Diarrhea and cramping; abortifacient |
| Standard-dose H2RA | Does not prevent NSAID-associated gastric ulcers; not recommended for this purpose[13][15] | — |
Lifestyle and Dietary Modification
Evidence for lifestyle prevention of FD derives almost entirely from trials in symptomatic patients; dedicated primary prevention trials are lacking, and guidelines disagree on benefit.[1][4]
- Diet: A 2026 UK RCT found a low-FODMAP diet superior to traditional dietary advice in postprandial distress syndrome (adequate relief 71% vs 35%).[18] Supportive data include a Belgian trial and an earlier RCT favoring low-FODMAP in the bloating/PDS subgroup, and a 2026 systematic review.[19][20][21] In contrast, a 2026 NEJM review concludes neither simple dietary advice nor low-FODMAP diets have been shown superior in rigorous trials.[4] Traditional advice (small, frequent, low-fat meals; limiting caffeine, alcohol, carbonated, spicy, and processed foods) is low-risk and reasonable.[20]
- Physical activity: Mendelian randomization combined with an RCT associated moderate-intensity exercise with lower FD risk and higher adequate relief (47% vs 31%); a 2025 meta-analysis (15 RCTs, 1,359 patients) reported improved symptoms, quality of life, and sleep.[22][23] High-intensity or prolonged exercise can provoke GI symptoms via splanchnic hypoperfusion.[24] The 2020 Lancet review found little high-quality evidence that exercise alters FD.[1]
- Smoking: A consistent, likely causal PUD risk factor; ulcer risk remains elevated after cessation relative to never-smokers, making prevention of initiation the key target. Offer evidence-based smoking cessation to all smokers.[7]
- Alcohol and coffee: A 2024 JAMA review concludes neither is a PUD risk factor; other cohorts implicate heavy alcohol intake. Counsel moderation without asserting a causal link.[7]
- Post-infectious FD: Acute enteric infection (bacterial, viral, or parasitic) approximately doubles to triples the risk of subsequent FD (pooled OR ~2.2–2.5; mean prevalence ~9.6% after gastroenteritis), with risk highest in the first 12 months.[25][26][1] Food, water, and hand hygiene are the relevant preventive measures, although direct primary prevention trials are lacking.
Clinical Recommendations
- Consider opportunistic H. pylori screening in individuals at increased gastric cancer risk, with household testing of infected individuals; confirm eradication after treatment.[11]
- Before long-term NSAID or aspirin therapy, assess GI and CV risk, test and treat H. pylori, and provide gastroprotection (PPI co-therapy; COX-2 inhibitor plus PPI for high GI risk) in at-risk patients.[3][13]
- Offer smoking cessation to all smokers and counsel alcohol moderation.[7]
- In patients prone to FD, dietitian-guided dietary modification and moderate exercise may be offered as low-risk measures of modest, uncertain benefit.[18][22][4]
- Set expectations before eradication: most H. pylori-positive FD patients will not become symptom-free, so persistent symptoms should not be attributed to reinfection by default.[2][27]
Common Pitfalls
- Using serology for screening or test of cure instead of urea breath or stool antigen testing.[11]
- Omitting confirmation of eradication.[11]
- Relying on standard-dose H2RAs for NSAID gastroprotection.[13][15]
- Prescribing a COX-2 inhibitor without a PPI in high-GI-risk patients, or ignoring the added CV risk.[3]
- Overstating FD prevention from diet or exercise given conflicting evidence.[1][4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ (2020). "Functional dyspepsia". Lancet. 396 (10263): 1689–1702. doi:10.1016/S0140-6736(20)30469-4.
- ↑ 2.0 2.1 2.2 Ford AC, Tsipotis E, Yuan Y, Leontiadis GI, Moayyedi P (2022). "Efficacy of eradication therapy for functional dyspepsia: updated systematic review and meta-analysis". Gut. doi:10.1136/gutjnl-2021-326583.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Almadi MA, Lu Y, Alali AA, Barkun AN (2024). "Peptic ulcer disease". Lancet. 404 (10447): 68–81. doi:10.1016/S0140-6736(24)00155-7.
- ↑ 4.0 4.1 4.2 4.3 4.4 Pasricha PJ, Talley NJ (2026). "Functional dyspepsia". N Engl J Med. 394 (2): 166–176. doi:10.1056/NEJMcp2501860.
- ↑ 5.0 5.1 5.2 5.3 Mülder DT, O'Mahony JF, Kapteijn N; et al. (2026). "The disease burden of Helicobacter pylori beyond gastric cancer: quantifying the forgotten potential benefits of mass eradication". Gastroenterology. 170 (2): 344–352. doi:10.1053/j.gastro.2025.08.015.
- ↑ 6.0 6.1 6.2 Ford AC, Yuan Y, Park JY, Forman D, Moayyedi P (2025). "Eradication therapy to prevent gastric cancer in Helicobacter pylori-positive individuals: systematic review and meta-analysis of randomized controlled trials and observational studies". Gastroenterology. 169 (2): 261–276. doi:10.1053/j.gastro.2024.12.033.
- ↑ 7.0 7.1 7.2 7.3 Vakil N (2024). "Peptic ulcer disease: a review". JAMA. 332 (21): 1832–1842. doi:10.1001/jama.2024.19094.
- ↑ Malfertheiner P, Camargo MC, El-Omar E; et al. (2023). "Helicobacter pylori infection". Nat Rev Dis Primers. 9 (1): 19. doi:10.1038/s41572-023-00431-8.
- ↑ Lee YC, Chen TH, Chiu HM; et al. (2013). "The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention". Gut. 62 (5): 676–682. doi:10.1136/gutjnl-2012-302240.
- ↑ Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P (2020). "Helicobacter pylori eradication for the prevention of gastric neoplasia". Cochrane Database Syst Rev. 7: CD005583. doi:10.1002/14651858.CD005583.pub3.
- ↑ 11.0 11.1 11.2 11.3 11.4 11.5 11.6 Shah SC, Wang AY, Wallace MB, Hwang JH (2025). "AGA Clinical Practice Update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: expert review". Gastroenterology. 168 (2): 405–416.e1. doi:10.1053/j.gastro.2024.11.001.
- ↑ Liou JM, Malfertheiner P, Hong TC; et al. (2025). "Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II". Gut. doi:10.1136/gutjnl-2025-335297.
- ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology (2009). "Guidelines for prevention of NSAID-related ulcer complications". Am J Gastroenterol. 104 (3): 728–738. doi:10.1038/ajg.2009.115.
- ↑ Crowe SE (2019). "Helicobacter pylori infection". N Engl J Med. 380 (12): 1158–1165. doi:10.1056/NEJMcp1710945.
- ↑ 15.0 15.1 15.2 15.3 15.4 Lanas A, Chan FKL (2017). "Peptic ulcer disease". Lancet. 390 (10094): 613–624. doi:10.1016/S0140-6736(16)32404-7.
- ↑ Garegnani L, Oltra G, Burgos MA; et al. (2025). "Proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug-induced ulcers and dyspepsia". Cochrane Database Syst Rev. 5: CD014585. doi:10.1002/14651858.CD014585.pub2.
- ↑ Yuan JQ, Tsoi KK, Yang M; et al. (2016). "Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity". Aliment Pharmacol Ther. 43 (12): 1262–1275. doi:10.1111/apt.13642.
- ↑ 18.0 18.1 Shiha MG, Buckle RL, Shaw CC, Aziz I (2026). "Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet vs traditional dietary advice in postprandial functional dyspepsia: a randomized clinical trial". Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2026.06.006.
- ↑ Van den Houte K, Broeders B, Tóth J; et al. (2025). "Outcome of a FODMAP restriction diet with subsequent blinded reintroduction in functional dyspepsia/postprandial distress syndrome". Gut. doi:10.1136/gutjnl-2024-334156.
- ↑ 20.0 20.1 Goyal O, Nohria S, Batta S; et al. (2022). "Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet versus traditional dietary advice for functional dyspepsia: a randomized controlled trial". J Gastroenterol Hepatol. 37 (2): 301–309. doi:10.1111/jgh.15694.
- ↑ Katsumata R, Shinozaki S, Oshima T; et al. (2026). "Therapeutic potential of the low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet in functional dyspepsia: a systematic review". Digestion: 1–11. doi:10.1159/000551300.
- ↑ 22.0 22.1 Wei Z, Tao Z, Hao Y; et al. (2026). "The effects of physical activity on functional dyspepsia: a Mendelian randomization and randomized controlled study". J Neurogastroenterol Motil. 32 (3): 405–416. doi:10.5056/jnm25159.
- ↑ Huang Z, Zhuang Y, Lin T, Liu S, Wu J (2025). "Efficacy of exercise therapies on functional dyspepsia: a systematic review and meta-analysis". Dig Liver Dis. doi:10.1016/j.dld.2025.06.004.
- ↑ Costa RJS, Snipe RMJ, Kitic CM, Gibson PR (2017). "Systematic review: exercise-induced gastrointestinal syndrome—implications for health and intestinal disease". Aliment Pharmacol Ther. 46 (3): 246–265. doi:10.1111/apt.14157.
- ↑ Pike BL, Porter CK, Sorrell TJ, Riddle MS (2013). "Acute gastroenteritis and the risk of functional dyspepsia: a systematic review and meta-analysis". Am J Gastroenterol. 108 (10): 1558–1563. doi:10.1038/ajg.2013.147.
- ↑ Futagami S, Itoh T, Sakamoto C (2015). "Systematic review with meta-analysis: post-infectious functional dyspepsia". Aliment Pharmacol Ther. 41 (2): 177–188. doi:10.1111/apt.13006.
- ↑ Sayuk GS, Gyawali CP (2020). "Functional dyspepsia: diagnostic and therapeutic approaches". Drugs. 80 (13): 1319–1336. doi:10.1007/s40265-020-01362-4.